Cellectar

#药闻简讯# 2025 年 10 月 6 日，专注于癌症治疗药物发现和开发的后期临床试验生物制药公司$Cellectar(CLRB)$ 今日宣布，经过科学建议程序，欧洲药品管理局（EMA）的科学建议工作组（SAWP）建议，对于 iopofosine I 131 作为治疗布鲁顿酪氨酸激酶抑制剂（BTKi）难治性 Waldenstrom 巨球蛋白血症（W...

$Cellectar(CLRB)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001753926-25-001260  Act: 34  Size: 17 KB 网页链接

$Cellectar(CLRB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-25-078102  Act: 34  Size: 299 KB 网页链接

$Cellectar(CLRB)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000935836-25-000536  Act: 34  Size: 6 KB 网页链接

$Cellectar(CLRB)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001104659-25-096928  Act: 34  Size: 236 KB 网页链接

$Cellectar(CLRB)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001104659-25-078706  Act: 34  Size: 10 KB 网页链接

$Cellectar(CLRB)$ 8-K Current report, items 1.01, 2.02, 3.02, 3.03, 8.01, and 9.01 Accession Number: 0001104659-25-098725  Act: 34  Size: 542 KB 网页链接

$Cellectar(CLRB)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001104659-25-078835  Act: 34  Size: 14 KB 网页链接

$Cellectar(CLRB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001410578-25-001778  Act: 34  Size: 5 MB 网页链接